Sort   by:  
 Page size 
primary ALL cells (B-lineage) resistant to vincristine by the MTT in vitro sensitivity assay
ORGANISM(S): Homo sapiens 
primary ALL cells (B- and T-lineage) resistant to vincristine by the MTT in vitro sensitivity assay
ORGANISM(S): Homo sapiens 
primary ALL cells (B-lineage) sensitive to vincristine by the MTT in vitro sensitivity assay
ORGANISM(S): Homo sapiens 
Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause of treatment failure in the remaining patients is unknown. We determined the sensitivity of ALL cells to individual antileukemic agents in 441 patients, and used a genome-wide approac...
ORGANISM(S): Homo sapiens 
primary ALL cells (B- and T-lineage) sensitive to vincristine by the MTT in vitro sensitivity assay
ORGANISM(S): Homo sapiens 
Gene expression profiles were assessed for vincristine-sensitive parental ovarian tumor cell line (SKOV3) and its highly vincristine-resistant derivative (SKVCR 2.0) Experiment Overall Design: Duplicate gene expression microarray experiments were undertaken for each of SKOV3 and SKVCR 2.0. Comparat...
ORGANISM(S): Homo sapiens 
The development of a clinically relevant xenograft model of pediatric acute lymphoblastic leukemia, using a 4-drug treatment regimen designed to mimic pediatric remission induction therapy. Relapse and acquired drug resistance in T-cell acute lymphoblastic leukemia (T-ALL) remains a significant clin...
ORGANISM(S): Homo sapiens 
H3K27me3 ChIP-seq was performed on: 1) untreated SH-SY5Y human neuroblastoma cells (day 0) 2) vincristine-treated SH-SY5Y human neuroblastoma cells (7 days of treatment - day 7) 3) vincristine-treated SH-SY5Y human neuroblastoma cells (7 days of treatment + 7 days of recover - day 14)
ORGANISM(S): Homo sapiens 
WGBS was performed on: 1) untreated SH-SY5Y human neuroblastoma cells (day 0) 2) vincristine-treated SH-SY5Y human neuroblastoma cells (7 days of treatment - day 7) 3) vincristine-treated SH-SY5Y human neuroblastoma cells (7 days of treatment followed by 7 days of recovery - day 14)
ORGANISM(S): Homo sapiens 
This study investigates the synergistic antitumor efficacy of a triple combination therapy—Nisin (N), Urolithin B (UB), and Vincristine (Vinc)—against human HBK11 lymphoma cells, with an emphasis on proteomic mechanisms of action. The findings elucidate the molecular underpinnings of this novel comb...
ORGANISM(S): Homo sapiens (Human) 
2025-09-19 | PXD065631 | Pride
Sort   by:  
 Page size